Acetaminophen use in pregnancy and autism: separating controversy from scientific evidence

Acetaminophen (paracetamol) has long been recommended as the preferred first-line analgesic and antipyretic in pregnancy, supported by decades of clinical experience, and has a more favorable safety profile than nonsteroidal anti-inflammatory drugs or opioids. Recently, however, political statements and media coverage linking maternal tylenol use to autism risk have amplified public concern and created uncertainty in clinical practice. This narrative review summarizes the current epidemiological evidence and positions of major professional societies and regulatory agencies on prenatal acetaminophen exposure and neurodevelopmental outcomes. A large Swedish nationwide cohort with a siblingcontrol analysis found no significant association between acetaminophen use during pregnancy and children's risk of autism spectrum disorder, attentiondeficit/hyperactivity disorder, or intellectual disability, suggesting that the previously reported modest risk elevations largely reflect confounding and methodological limitations. Similar null findings from other high-quality cohort and siblingcomparison studies indicate no causal relationship between therapeutic prenatal acetaminophen use and major neurodevelopmental disorders. Consistent with these data, organizations such as the World Health Organization, American College of Obstetricians and Gynecologists, and national regulators continue to endorse short-term guideline-concordant acetaminophen use as appropriate in pregnancy. In routine obstetric care, emphasis should be placed on maternal safety, fetal well-being, and evidence-based counseling rather than non-evidencebased concerns, with acetaminophen used at the lowest effective dose for the shortest necessary duration unless future high-quality data indicate otherwise.